Provention Bio, Inc. today announced it’s putting type 1 diabetes (T1D) to the test during Diabetes Awareness Month this November.
RED BANK, N.J., Nov. 9, 2021 /PRNewswire/ -- Provention Bio (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced it’s putting type 1 diabetes (T1D) to the test during Diabetes Awareness Month this November. The company is calling on the T1D community to take the #Type1TestedPledge to spread awareness about risk factors and the importance of screening people with a family history of T1D for early-stage, pre-symptomatic disease. Screening may reduce the risk of serious complications and life-threatening events such as diabetic ketoacidosis. It can also allow time to prepare for the onset of clinical disease and a lifetime of insulin administration and glucose monitoring. T1D is an autoimmune disease affecting 1.6 million Americans and another 300,000-400,000 Americans have early-stage disease, which may have no symptoms and go unnoticed while the insulin-producing cells are progressively destroyed. Family history puts people at up to 15 times greater risk of developing T1D. The disease can be detected in the earliest stages - before symptoms occur - through a blood test for certain autoantibodies. Data show 75% of people with these autoantibodies will go on to develop clinical, or insulin-dependent, T1D within five years, and their lifetime risk is almost 100%. “The #Type1TestedPledge is deeply rooted in Provention Bio’s mission to seek out and target autoimmunity early. It builds on our successful ‘Type 1 Tested’ campaign and national effort to redefine patient care in T1D,” said Jason Hoitt, Chief Commercial Officer, Provention Bio. The campaign will be featured on Type 1 Tested and other social media and digital channels, with support from leading patient advocacy organizations. People can get involved with the campaign by pledging to:
Go to www.type1tested.com to learn more about the #Type1TestedPledge campaign and join the Type 1 Tested community on Instagram and Facebook. About Provention Bio, Inc. Internet Posting of Information Investor Contacts: Sam Martin, Argot Partners Media Contact:
SOURCE Provention Bio, Inc. | ||
Company Codes: NASDAQ-NMS:PRVB |